腺素对瘤适应性免疫和干预策略的抑制作用
Longsheng Wang1, Jie Zhang1, Wenxin Zhang1
1Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Acta pharmaceutica Sinica. B
|May 27, 2024
概括
瘤微环境中的腺素 (Ado) 通过抑制免疫细胞功能和贩运来抑制抗瘤免疫力. 向腺路径可以增强抗癌免疫反应和免疫疗法的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在瘤微环境 (TME) 中,腺素 (Ado) 水平升高.
- 腺素与腺素受体 (AdoRs) 结合,抑制适应性抗瘤免疫力.
- 这种抑制涉及多种机制,影响免疫细胞及其功能.
研究的目的:
- 总结和分析腺对瘤适应性免疫的抑制作用.
- 阐明腺的免疫抑制背后的分子机制.
- 提供针对癌症中腺路径的治疗策略的概述.
主要方法:
- 关于腺在瘤免疫力中的作用的临床前和临床研究的综述.
- 分析受腺影响的分子通路,包括MHC II,共刺激因子,细胞因子和免疫检查点.
- 检查腺对树突细胞,巨细胞和T细胞的影响.
主要成果:
- 氨酸降低了MHC II和对抗原呈现细胞的共刺激因子的调节,从而降低了抗原呈现.
- 氨酸抑制T细胞受体信号传递,抗瘤细胞因子分泌和T细胞透.
- 氨酸通过促进免疫抑制因子和增强免疫检查点活性来降低T细胞细胞毒性.
结论:
- 减少腺的产生或阻断AdoRs可以增强抗瘤免疫反应.
- 向腺路径是改善癌症免疫治疗疗效的有希望的策略.
- 针对腺生成或AdoRs的抑制剂的进一步开发对于临床应用至关重要.
相关概念视频
Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cytotoxic T Cells-mediated Immune Response
892
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
892


